DailyDoctor Archive Specialties Get app
All internal medicine briefings

The edition · Internal Medicine

ACP puts hormone therapy first for menopausal hot flushes

A physician guideline ranks the drug options for vasomotor symptoms; a randomised trial says not to pause biologics for vaccination; and the fracture-treatment gap persists.

The edition in brief

The American College of Physicians has issued a guideline on drug treatment for menopausal vasomotor symptoms in outpatient care: oestrogen with a progestogen, or oestrogen alone after hysterectomy, as first line on high-certainty evidence; venlafaxine or desvenlafaxine second; and escitalopram, paroxetine, gabapentin or a neurokinin receptor antagonist third. The COVER trial randomised 840 people with inflammatory arthritis to continue or pause biologic or JAK inhibitor therapy for two weeks after a COVID-19 booster: pausing did not improve antibody response but more than doubled the odds of a flare. A US claims cohort of nearly 468,000 women found a one-in-five risk of a second fracture within two years of the first, yet only 17.5% started osteoporosis treatment. A single-centre study suggests the cirrhosis threshold of 250 neutrophils is a poor guide to bacterial peritonitis in malignant ascites. In 21 veterans' hospitals, 42% of medical inpatients were medically ready to leave on a given day and 18% had waited a week or more, mostly for long-term care. The pearl covers the fracture that should trigger treatment.

In this edition

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this one is waiting in it.

QR code to install Daily Doctor
Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.

Tomorrow morning, before your first patient

One edition a day for internal medicine, written by the desk, every claim tied to its paper. Six minutes.

Get the app — free